Targeted
Medical Pharma, Inc. (OTCQB: TRGM), announced today the launch of a
new e-prescribing
platform for the medical food, Theramine. The secure online
e-prescribing portal is available to healthcare providers in the United
States, interested in a clinically validated, peer reviewed,
non-pharmacologic alternative to narcotic and NSAID pain medications for
patients suffering from pain syndromes.
Theramine
is a medical food indicated for the dietary management of
pain syndromes, and has been the subject of two double-blind,
randomized, multi-center
trials, which compared Theramine to low dose naproxen and
ibuprofen. 256 subjects participated in the two studies across 10
independent sites that were randomized for treatment to receive Theramine
alone (two capsules twice daily), NSAID or a combination of both. In
both studies, Theramine showed a statistically significant
reduction in inflammation and improvement in low back pain than either
naproxen at 250mg daily or ibuprofen at 400mg daily.
“Clinical evidence suggests that by addressing the increased amino acid
requirements of pain syndromes you can significantly improve pain
perception and reduce inflammation,” said William Shell M.D., CEO and
Chief Science Officer at Targeted Medical Pharma. “Theramine is a
very useful clinical tool for physicians interested in managing pain and
inflammation without the GI or cardiovascular side effects associated
with NSAIDs or the addictive potential of narcotics.”
Visit https://tmedpharma.com/secure/eprescribe
for more information about e-prescribing Theramine or any other
Targeted Medical Pharma products.
Twitter: @tmedpharma
Facebook: www.facebook.com/targetedmedicalpharma
About Targeted Medical Pharma, Inc.
Targeted
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company also develops a line of dietary
supplements designed to support health and wellness. The company
manufactures 10 proprietary medical foods, and recently launched its
first dietary supplement, Clearwayz™.
The products are sold directly to physicians and pharmacies in the U.S.
The company also is developing nutrient-based systems for oral
stimulation of progenitor stem cells that differentiate into neurons,
red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma’s business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaims any obligation
or undertaking to update or revise any forward-looking statement
contained herein to reflect any change in the company's expectations
with regard thereto or any change in events, conditions or circumstances
upon which any statement is based.
Copyright Business Wire 2014